Disease · MONDO_0018876

mantle cell lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. mantle cell lymphoma. Diseases, record MONDO_0018876. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018876

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: mantle cell lymphoma; Open Targets
Open Targets ID: MONDO_0018876; Open Targets
Other names: LCM, MCL, classical mantle cell lymphoma, mantle zone lymphoma; Open Targets
Disease Ontology: DOID:0050746; Disease Ontology
MeSH: D020522; MeSH
NCI Thesaurus: C4337; NCI Thesaurus
Orphanet: ORPHA:52416; Orphanet
Highest stage of its drugs: Approval, for 13 of its 189 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs189

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Approval	ClinicalTrials.gov	66	66	64	Drugs and targets
IBRUTINIB	CHEMBL1873475	Small molecule	Approval	ClinicalTrials.gov, DailyMed, EMA Human Drugs and TTD	66	63	63	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Approval	TTD	49	48	48	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Approval	DailyMed and EMA Human Drugs	46	43	43	Drugs and targets
ACALABRUTINIB	CHEMBL3707348	Small molecule	Approval	DailyMed, FDA and TTD	36	33	33	Drugs and targets
ZANUBRUTINIB	CHEMBL3936761	Small molecule	Approval	DailyMed, FDA and TTD	30	27	27	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Approval	ClinicalTrials.gov	26	26	26	Drugs and targets
TEMSIROLIMUS	CHEMBL1201182	Small molecule	Approval	EMA Human Drugs	12	11	11	Drugs and targets
PIRTOBRUTINIB	CHEMBL4650485	Small molecule	Approval	EMA Human Drugs, FDA and PMDA	13	10	10	Drugs and targets
BREXUCABTAGENE AUTOLEUCEL	CHEMBL4594618	Gene	Approval	ClinicalTrials.gov, EMA Human Drugs and TTD	10	8	8	Drugs and targets

1 to 10 of 189

See all 189 drugs

Targets203

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	10	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
BTK	Tyrosine-protein kinase BTK	9	Tyrosine-protein kinase BTK inhibitor	Approval	https://conductscience.org/library/genes/695	Drugs and targets
CD19	B-lymphocyte antigen CD19	6	B-lymphocyte antigen CD19 binding agent	Approval	https://conductscience.org/library/genes/930	Drugs and targets
PIK3CD	PI3-kinase class I	6	PI3-kinase class I inhibitor; PI3-kinase p110-delta subunit inhibitor	Phase 3	https://conductscience.org/library/genes/5293	Drugs and targets
SYK	Tyrosine-protein kinase SYK	6	Tyrosine-protein kinase SYK inhibitor	Phase 2	https://conductscience.org/library/genes/6850	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	6	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
HDAC6	Histone deacetylase	5	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Phase 2	https://conductscience.org/library/genes/10013	Drugs and targets
ADRM1	26S proteasome	4	26S proteasome inhibitor	Approval	https://conductscience.org/library/genes/11047	Drugs and targets
BCL2	Apoptosis regulator Bcl-2	4	Apoptosis regulator Bcl-2 inhibitor	Phase 3	https://conductscience.org/library/genes/596	Drugs and targets
CDK4	Cyclin-dependent kinase	4	Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor; Cyclin-dependent kinase inhibitor	Phase 2	https://conductscience.org/library/genes/1019	Drugs and targets

1 to 10 of 203

See all 203 targets

Trials444

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00700258	Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]		1,520	2024-09-23	Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors	AXITINIB, SUNITINIB, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT01776840	A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma	Phase 3	523	2022-07-26	Mantle Cell Lymphoma	BENDAMUSTINE, IBRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT01996865	Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.	Phase 3	503	2025-07-10	Lymphoma, Non-Hodgkin	LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00722137	Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma	Phase 3	487	2014-11-17	Mantle Cell Lymphoma	BORTEZOMIB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00877006	Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study	Phase 3	447	2014-04-28	Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma	BENDAMUSTINE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01415752	Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma	Phase 2	373	2025-04-08	Lymphoma, Mantle Cell Lymphoma	BENDAMUSTINE, BORTEZOMIB, LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03112174	Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)	Phase 3	366	2025-07-22	Mantle-Cell Lymphoma	IBRUTINIB, VENETOCLAX	Its record names the disease	ClinicalTrials.gov
NCT00269113	A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma	Phase 3	360	2015-07-23	Non-Hodgkin's Lymphoma	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01799889	Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies	Phase 2	326	2020-09-23	Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma	ENTOSPLETINIB	Its record names the disease	ClinicalTrials.gov
NCT00305682	Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant	Phase 2	295	2020-11-02	Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes	CYCLOPHOSPHAMIDE, FLUDARABINE, MYCOPHENOLATE MOFETIL, SIROLIMUS	Its record names the disease	ClinicalTrials.gov

1 to 10 of 444

See all 444 trials

Comparisons in its trials54

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Placebo + Bendamustine and Rituximab (BR) (Treatment A) vs Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B): deaths from any cause	129 of 262	120 of 261	523	NCT01776840	Trial comparisons
Placebo + Bendamustine and Rituximab (BR) (Treatment A) vs Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B): Number of Participants With Treatment-emergent Adverse Events (TEAEs)	257 of 260	259 of 259	519	NCT01776840	Trial comparisons
Placebo + Bendamustine and Rituximab (BR) (Treatment A) vs Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B): serious adverse events	157 of 260	201 of 259	519	NCT01776840	Trial comparisons
R-CHOP vs VcR-CAP: Number of Participants Experiencing an Adverse Event (AE)	239 of 242	240 of 240	482	NCT00722137	Trial comparisons
R-CHOP vs VcR-CAP: serious adverse events	72 of 242	91 of 240	482	NCT00722137	Trial comparisons
R-CHOP vs VcR-CAP: Overall Response Rate (ORR)	204 of 228	211 of 229	457	NCT00722137	Trial comparisons
Bendamustine and Rituximab (BR) vs R-CHOP/R-CVP: Participants With Disease Progression, Relapse or Death At the End of the Treatment Period or the Long-Term Follow-up Period	36 of 224	30 of 223	447	NCT00877006	Trial comparisons
Bendamustine and Rituximab (BR) vs R-CHOP/CVP: serious adverse events	60 of 221	49 of 215	436	NCT00877006	Trial comparisons
Mitoxantrone, Chlorambucil, Prednisolone (MCP) vs Rituximab + MCP: serious adverse events	20 of 177	18 of 183	360	NCT00269113	Trial comparisons
Ibrutinib vs Temsirolimus: Number of Participants With Biomarkers That Alter B-cell Receptor (BCR) Signaling or Activate Alternative Signaling Pathways and to Explore Their Association With Response or Resistance to Ibrutinib	61 of 139	53 of 141	280	NCT01646021	Trial comparisons

1 to 10 of 54

See all 54 comparisons in its trials

Papers from its trials297

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42209393	RESULT	1	PubMed
38889737	RESULT	1	PubMed
38837078	RESULT	1	PubMed
38820500	RESULT	1	PubMed
36548927	RESULT	1	PubMed
34152395	RESULT	1	PubMed
33735476	RESULT	2	PubMed
33181832	RESULT	1	PubMed
32461234	RESULT	1	PubMed
32126141	RESULT	2	PubMed

1 to 10 of 297

See all 297 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018876

GET https://conductscience.org/api/diseases/v1/MONDO_0018876/drugs?page=2

API reference For AI assistants